Post-recovery enhancement of anti-variant neutralisation after severe COVID-19

Affiliations

¹ Center for Nephrology at the Seventh Hospital, Sun Yat-sen University, Shenzhen, China; Department of Biomedical Science, City University of Hong Kong, Kowloon Tong, Hong Kong Special Administrative Region, China.
² Laboratory of Clinical Immunology, Department of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
³ Department of Pathology, Mount Sinai St Luke's Roosevelt Hospital Center, New York, NY, USA.
⁴ Center for Nephrology at the Seventh Hospital, Sun Yat-sen University, Shenzhen, China; Division of Research and Development, US Department of Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY 11209, USA; Department of Cell Biology, State University of New York Downstate Health Science University, Brooklyn, NY, USA. Electronic address: peng.hong@downstate.edu.

Yingying Lu et al. Lancet Microbe. 2022 May.

. 2022 May;3(5):e330-e331.

doi: 10.1016/S2666-5247(22)00032-5. Epub 2022 Feb 7.

¹ Center for Nephrology at the Seventh Hospital, Sun Yat-sen University, Shenzhen, China; Department of Biomedical Science, City University of Hong Kong, Kowloon Tong, Hong Kong Special Administrative Region, China.
² Laboratory of Clinical Immunology, Department of Laboratory Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
³ Department of Pathology, Mount Sinai St Luke's Roosevelt Hospital Center, New York, NY, USA.
⁴ Center for Nephrology at the Seventh Hospital, Sun Yat-sen University, Shenzhen, China; Division of Research and Development, US Department of Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY 11209, USA; Department of Cell Biology, State University of New York Downstate Health Science University, Brooklyn, NY, USA. Electronic address: peng.hong@downstate.edu.

No abstract available

References

1. Stamatatos L, Czartoski J, Wan Y-H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021 doi: 10.1126/science.abg9175. published online March 25. - DOI - PMC - PubMed
1. Muecksch F, Weisblum Y, Barnes CO, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021;54:1853. 68.e7. - PMC - PubMed
1. Chen Y, Tong P, Whiteman NB, et al. Differential antibody dynamics to SARS-CoV-2 infection and vaccination. bioRxiv. 2021 doi: 10.1101/2021.09.09.459504. published online Sept 10. (preprint). - DOI
1. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization of the SARS-CoV-2 omicron variant. N Engl J Med. 2021 doi: 10.1056/NEJMc2119641. published online Dec 30. - DOI - PMC - PubMed
1. Carreno JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 omicron. Nature. 2021 doi: 10.1038/s41586-022-04399-5. published online Dec 31. - DOI - PubMed